Health Trials

CD7+ T-ALL/LBL

2

Review clinical trials related to CD7+ T-ALL/LBL. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population. Secondary objectives include evaluating the pharmacokinetics/pharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.

Participants needed: 12
Trial details
Phase: Phase 1Age: 3-18Biological sex: AllType: InterventionalSponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Updated: Jun 3, 2026Locations: 1
Eligibility criteria

(1) Aged from 3 to 18 years (inclusive), with no restriction on gender. (2) Expe... [+6]

(1) Patients judged by the investigator to require long-term use of immunosuppre...

Read more
Status: Recruiting

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation

Participants needed: 18
Trial details
Phase: Phase 1Age: 3-80Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: Dec 12, 2025Locations: 1
Eligibility criteria

(1) The subject or the legal guardian understands and voluntarily signs the info... [+6]

Subjects with any of the following conditions will not be eligible for inclusion... [+21]

Read more